Identification of key genes involved in nasopharyngeal carcinoma

Xue Jiang, Lichun Feng, Baoqiang Dai, Liping Li, Weiwei Lu

Cangzhou Central Hospital, Department of Otorhinolaryngology, Cangzhou, Hebei, China

Received 18 May 2016; accepted 11 September 2016
Available online 26 September 2016

KEYWORDS
Nasopharyngeal carcinoma; Differentially expressed genes; Enrichment analysis; Regulatory network

Abstract
Introduction: Nasopharyngeal carcinoma is the most common cancer originating from the nasopharynx.
Objective: To study the mechanisms of nasopharyngeal carcinoma, we analyzed GSE12452 microarray data.
Methods: GSE12452 was downloaded from the Gene Expression Omnibus database and included 31 nasopharyngeal carcinoma samples and 10 normal nasopharyngeal tissue samples. The differentially expressed genes were screened by ANOVA in the PGS package. Using the BINGO plugin in Cytoscape and pathway enrichment analysis in the PGS package, functional and pathway enrichment analyses were performed separately to predict potential functions of the differentially expressed genes. Furthermore, Transcription factor-differentially expressed gene pairs were searched, and then the transcription factor-differentially expressed gene regulatory network was visualized using Cytoscape software.
Results: A total of 487 genes were screened as differentially expressed genes between the nasopharyngeal carcinoma samples and the normal nasopharyngeal tissue samples. Enrichment analysis indicated that PTGS2 was involved in the regulation of biological process and small cell lung cancer. ZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2 → PTGS2 and OVOL1 → CXCL10).
Conclusion: PTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.

© 2016 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Please cite this article as: Jiang X, Feng L, Dai B, Li L, Lu W. Identification of key genes involved in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2017;83:670–6.
* Corresponding author.
E-mail: 13933985866@163.com (W. Lu).
Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
http://dx.doi.org/10.1016/j.bjorl.2016.09.003
1808-8694/© 2016 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction

As the most common cancer originating from the nasopharynx, nasopharyngeal carcinoma (NPC) caused approximately 86,700 new cases and 50,800 deaths globally in 2012. NPC is extremely common in Southeast Asia and southern China, with more than 50,000 new cases each year. NPC can be induced by multiple factors including heredity, viral factors and environmental influences. Most cases of NPC are correlated with Epstein–Barr Virus (EBV) infection, which is a B-lymphotropic herpesvirus possessing growth-transforming properties. Therefore, it is of great importance to study the mechanisms of NPC.

Many studies investigating the mechanisms of NPC have been published. There are several genes (such as C-myc, AKT1, p53, MDM2, LMP1 and PTEN) implicated in the pathogenesis of NPC because they are often amplified or altered in patients with this disease. Disabled 2 (DAB2) is frequently down-regulated by promoter hypermethylation and may be a potential tumor suppressor in NPC. Previous studies show that the potential tumor suppressor gene A disintegrin-like and metalloprotease domain with thrombospondin type 1 motifs 9 (ADAMTS9) is closely related to lymph node metastases, and it can inhibit tumor growth by suppressing angiogenesis in NPC. The transcription factor (TF) adaptor-related protein 1 (AP-1) activated by the EBV-encoded Nuclear Antigen 1 (EBNA1) can target hypoxia-inducible factor-1α, interleukin 8 and Vascular Endothelial Growth Factor (VEGF), which promotes microtubule formation in NPC cells. The TF Forkhead Box M1 (FOXM1) is involved in tumor development, and the adenovirus vector AdFOXM1shRNA, which expresses FOXM1-specific short hairpin RNA, may be used as a therapeutic intervention for the treatment of patients with NPC. By down-regulating the expression of Secreted Protein, Acidic and Rich in Cysteine (SPARC), TF sex determining region Y-box 5 (SOX-5) functions in the progression of NPC and may be used as a predictor for poor NPC prognosis. Although these studies have been performed to investigate NPC, the mechanisms of NPC still remain unclear.

In 2006, Sengupta et al. analyzed the expression of all latent EBV genes between NPC samples and normal nasopharyngeal epithelium samples, and obtained a panel of differentially expressed genes (DEGs). Using the same data that was used by Sengupta et al., we not only screened the DEGs but also performed a comprehensive bioinformatic analysis to identify key genes associated with NPC. The potential functions of the DEGs were predicted by functional and pathway enrichment analyses. In addition, a TF-DEG regulatory network was constructed to investigate the regulatory relationships between TFs and DEGs.

Methods

Microarray data

The GSE12452 expression profile data deposited by Sengupta et al. was downloaded from the Gene Expression Omnibus ( GEO, http://www.ncbi.nlm.nih.gov/geo/) database, which was based on the platform of the GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. The specimens included 31 NPC samples and 10 normal nasopharyngeal tissue samples collected from patients from Taiwan with informed consent. The samples were resected, fast frozen and then stored in liquid nitrogen.
Screening for DEGs

For the GSE12452 dataset, the Robust MultiArray Averaging (RMA) method in the Partek® Genomics Suite™ (PGS) (http://www.partek.com/) package was used for preprocessing, including background adjustment, quantile normalization and log2 transformation. After batch correction, the processed expression matrix was obtained. The ANOVA (analysis of variance) method in the PGS package was used to compare the DEGs between the NPC samples and the normal nasopharyngeal tissue samples. The p-values obtained were adjusted for multiple testing using the Benjamini and Hochberg method. Genes with fold-change (FC) >2 and adjusted p-value < 0.05 were selected as DEGs.

Functional and pathway enrichment analysis

Gene Ontology (GO) terms can be used to describe three types of gene products including biological process in which they implicated, their molecular function and subcellular location. The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database composed of genes and their functional information. Using the BiNGO plugin in Cytoscape (http://www.cytoscape.org/) and pathway enrichment analysis in the PGS package, GO and KEGG pathway enrichment analyses were performed separately for DEGs between the NPC samples and the normal nasopharyngeal tissue samples. The adjusted p-value < 0.05 was used as the cut-off criterion.

TF-DEG regulatory network construction

The Genomatix Software Suite (https://www.genomatix.de/) package was used to predict Transcription Factors (TFs). In brief, the Gene2Promoter (http://www.genomatix.de) tool was used to extract promoter sequences of corresponding DEGs from the Genomatix database. Then, the TFs were analyzed using the MatInspector tool. TFs with a p-value of <0.05 and FC >2 were selected as differentially expressed TFs, and then their corresponding TF-DEG pairs were screened. Finally, the TF-DEG regulatory network was visualized using Cytoscape software.

Results

Analysis of DEGs

After GSE12452 was downloaded, the expression profile data were preprocessed and then the DEGs were identified by ANOVA using the PGS package. The volcano plot for DEGs separately is shown in Fig. 1. A total of 487 genes were selected as DEGs between the NPC samples and the normal nasopharyngeal tissue samples, including 122 up-regulated and 365 down-regulated genes. The number of down-regulated genes was greater than the number of up-regulated genes. In the heat map of the hierarchical cluster analysis for the DEGs, the NPC samples and normal nasopharyngeal tissue samples were clearly divided into two groups (Fig. 2).

Functional and pathway enrichment analysis

The top 10 GO functions for the up-regulated genes included collagen fibril organization (p = 1.44E−06), extracellular matrix organization (p = 6.73E−08) and regulation of biological process (p = 3.35E−06, which involved prostaglandin-endoperoxide synthase 2, PTGS2) (Table 1A). The enriched KEGG pathways for the up-regulated genes are listed in Table 1C, and these included amoebiasis (p = 1.25E−07), ECM-receptor interaction (p = 9.01E−10) and small cell lung cancer (p = 3.10E−06, which involved PTGS2).
### Table 1: The enriched GO functions and KEGG pathways for the up-regulated and the down-regulated genes.

| Term                                               | Description                                                                 | Gene number | Gene symbol                                 | p-Value   |
|-----------------------------------------------------|-----------------------------------------------------------------------------|-------------|---------------------------------------------|-----------|
| **A**                                                |                                                                             |             |                                             |           |
| 30198                                               | Extracellular matrix organization                                          | 9           | COL1A1, COL4A2 . . . .                      | 6.73E-08  |
| 30199                                               | Collagen fibril organization                                               | 5           | COL3A1, COL1A2 . . . .                      | 1.44E-06  |
| 43062                                               | Extracellular structure organization                                       | 9           | COL3A1, COL1A2 . . . .                      | 2.85E-06  |
| 50789                                               | Regulation of biological process                                           | 72          | PTGS2, EZH2 . . . . .                       | 3.35E-06  |
| 32964                                               | Collagen biosynthetic process                                              | 3           | COL1A1, COL5A1, COL5A1 . . .               | 3.91E-06  |
| 43588                                               | Skin development                                                           | 5           | COL5A2, COL5A1 . . . .                      | 4.77E-06  |
| 65007                                               | Biological regulation                                                     | 74          | SLCA9A7, PTG52 . . . .                      | 6.95E-06  |
| 6950                                                | Response to stress                                                         | 30          | C3AR1, PTG52 . . . . .                      | 8.65E-06  |
| 9611                                                | Response to wounding                                                       | 15          | BMP2, TNFSF4 . . . . .                      | 1.03E-05  |
| 6954                                                | Inflammatory response                                                      | 11          | CXCL9, PLA2G7 . . . . .                     | 2.15E-05  |
| **B**                                                |                                                                             |             |                                             |           |
| 10880                                               | Regulation of release of sequestered calcium into cytosol by sarcoplasmic reticulum | 4           | CALM3, FKBP1B . . . .                      | 2.32E-07  |
| 30855                                               | Epithelial cell differentiation                                            | 13          | EREG, ELF3 . . . . .                       | 1.30E-06  |
| 60316                                               | Positive regulation of ryanodine-sensitive calcium-release channel activity | 3           | CALM2, CALM1, CALM1 . . .                   | 3.21E-06  |
| 60314                                               | Regulation of ryanodine-sensitive calcium-release channel activity         | 4           | FKBP1B, CALM2 . . . . .                     | 9.20E-06  |
| 60315                                               | Negative regulation of ryanodine-sensitive calcium-release channel activity | 3           | CALM3, CALM2, CALM1 . . .                   | 1.27E-05  |
| 7017                                                | Microtubule-based process                                                  | 14          | TPPP3, DNAH9 . . . . .                      | 1.92E-05  |
| 8544                                                | Epidermal development                                                     | 12          | CST6, EREG . . . . . .                      | 2.15E-05  |
| 1539                                                | Ciliary or flagellar motility                                              | 4           | TEKT2, DNAH2 . . . . .                      | 3.02E-05  |
| 7018                                                | Microtubule-based movement                                                | 9           | DNAH2, DNAH7 . . . . .                      | 3.72E-05  |
| 30216                                               | Keratinocyte differentiation                                              | 7           | PPL, CNFN . . . . . .                       | 3.90E-05  |
| **C**                                                |                                                                             |             |                                             |           |
| 1117                                                | ECM-receptor interaction                                                   | 11          | COL1A1, COL1A2 . . . .                      | 9.01E-10  |
| 1210                                                | Protein digestion and absorption                                          | 10          | COL1A2, COL3A1 . . . .                      | 9.05E-09  |
| 1010                                                | Amoebiasis                                                                 | 10          | CD14, COL1A2 . . . . .                      | 1.25E-07  |
| 9012                                                | Small cell lung cancer                                                    | 8           | PTG52, FN1 . . . . . .                      | 3.10E-06  |
| 9013                                                | Staphylococcus aureus infection                                            | 5           | C3AR1, FCGR2A . . . . .                     | 2.66E-04  |
| 9014                                                | Osteoclast differentiation                                                | 6           | SOCS1, TYK2 . . . . . .                     | 2.23E-03  |
| 9015                                                | Toll-like receptor signaling pathway                                       | 5           | CXCL9, NFKB1A . . . . .                     | 4.54E-03  |
| 9016                                                | DNA replication                                                           | 3           | PCNA, MCM2 . . . . . .                      | 6.36E-03  |
| 9017                                                | Leishmaniasis                                                             | 4           | FCGR2A, PTG52 . . . . .                     | 6.94E-03  |
| 9018                                                | Cell cycle                                                                | 5           | CCNE2, SMC1A . . . . .                      | 9.53E-03  |
| **D**                                                |                                                                             |             |                                             |           |
| 9019                                                | Drug metabolism-cytochrome P450                                             | 9           | ADH1C, ADH7 . . . . . .                     | 3.02E-07  |
| 8010                                                | Metabolism of xenobiotics by cytochrome P450                                 | 8           | ADH7, ALDH1A3 . . . . .                     | 8.48E-06  |
| 9011                                                | Tyrosine metabolism                                                       | 5           | ALDH3A1, ALDH3B2 . . . .                    | 1.69E-04  |
| 9012                                                | Glycolysis/gluconeogenesis                                                 | 6           | ADH7, ALDH1A3 . . . . .                     | 2.51E-04  |
| 9013                                                | Histidine metabolism                                                      | 4           | ALDH3A1, ALDH3A2 . . . .                    | 5.74E-04  |
| 9014                                                | beta-Alanine metabolism                                                    | 4           | ALDH3A2, ALDH3B2 . . . .                    | 6.59E-04  |
| 9015                                                | Phenylalanine metabolism                                                  | 3           | ALDH1A3, ALDH3A1, ALDH3B2                   | 1.88E-03  |
| 9016                                                | Tight junction                                                            | 7           | CGN, CLDN7 . . . . . .                      | 2.40E-03  |
| 9017                                                | Phototransduction                                                         | 3           | CALM1, CALM2, CALM3 . . .                   | 7.52E-03  |
| 9018                                                | Retinol metabolism                                                        | 4           | DHRS9, SDR16C5 . . . .                      | 1.03E-02  |
Similarly, functional and pathway enrichment analyses were performed for the down-regulated genes. As shown in Table 1B, the functions including the regulation of release of sequestered calcium ion into the cytosol by sarcoplasmic reticulum (p = 2.32E−07), epithelial cell differentiation (p = 1.30E−06) and positive regulation of ryanodine-sensitive calcium-release channel activity (p = 3.21E−06) were enriched. The enriched pathways included drug metabolism-cytochrome P450 (p = 3.02E−07), metabolism of xenobiotics by cytochrome P450 (p = 8.48E−06) and tyrosine metabolism (p = 1.69E−04) (Table 1D).

TF-DEG regulatory network analysis
Using the Genomatix Software Suite package, TFs were predicted for the 122 up-regulated and 365 down-regulated genes. There were up-regulated TFs targeting up-regulated or down-regulated genes, as well as down-regulated TFs targeting up-regulated or down-regulated genes. However, only TFs that targeted both up-regulated and down-regulated genes were selected. The TF-DEG regulatory network of TFs (Zic family member 2, ZIC2; ovo-like 1, OVOL1; and hairy and enhancer of split 1, HES1) and their targeted DEGs are shown in Fig. 3. In particular, significantly up-regulated PTGS2, fibronectin (FN1) and chemokine (C-X-C motif) ligand 9 (CXCL9) were targeted and activated by ZIC2. Nevertheless, significantly up-regulated chemokine (C-X-C motif) ligand 10 (CXCL10) was targeted and suppressed by OVOL1.

Figure 3  The regulatory network of Transcription Factors (TFs, such as ZIC2, OVOL and HES1) and their targeted differentially expressed genes (DEGs).

Discussion
In this study, a total of 487 genes were selected as DEGs between NPC samples and normal nasopharyngeal tissue samples, including 122 up-regulated and 365 down-regulated genes. There were many functions enriched for the DEGs, such as extracellular matrix organization and extracellular structure organization. PTGS2, FN1, CXCL9 and CXCL10 were significantly up-regulated genes involved in the TF-DEG regulatory network, and they may function in NPC through ZIC2 or OVOL1 (e.g., ZIC2→PTGS2 and OVOL1→CXCL10).

Enrichment analysis indicated that PTGS2 was involved in the regulation of biological process and small cell lung cancer. As a downstream gene involved in the NF-κB pathway, PTGS2 is also referred to as cyclooxygenase-2 (COX-2). It is known that COX2 can regulate cancer stem-like cells of NPC cells and promote their characteristics. Furthermore, parthenolide may function in targeted chemotherapy via the NF-κB/COX2 pathway. Based on PCR and restriction fragment length polymorphism analysis, the COX2 −765 G>C functional promoter polymorphism may be related to risk and neoplastic progression of NPC. The results of immunohistochemistry and semiquantitative assessment show that COX-2 expression increases as the nasopharyngeal epithelium develops from normal to dysplastic and then into NPC, indicating that COX-2 promotes the development of NPC. This suggests that PTGS2 might be associated with NPC.

It is known that FN1 contributes to tumorigenesis by promoting the growth and migration of tumor cells, as well as by...
enhancing resistance to therapy. Up-regulated FN1 correlates with the epithelial to mesenchymal transition (EMT) and contributes to tumor cell metastasis; therefore, it may be used as a potential diagnostic marker and therapeutic target of NPC. Based on a multiplex suspension array system, a previous study found that CXCL9 expression is significantly up-regulated in patients with NPC and oral cavity squamous cell carcinoma. Quantitative real-time PCR and immunohistochemistry suggested that up-regulated CXCL9 is related to the aggressiveness of NPC, and an enzyme-linked immunosorbent assay indicated that its serum level may be a valuable prognostic indicator. The ZIC genes, which consist of five Cys2His2 zinc-finger domains, encode zinc-finger Transcription Factors. Among the family members, ZIC2 mediates the tissue-specific expression of the G-protein coupled receptor dopamine receptor D1. ZIC2 expression is up-regulated in several malignant cancers, including synovial sarcoma, pediatric medulloblastoma and endometrial cancers. Therefore, the expression levels of FN1, CXCL9 and ZIC2 might be correlated with NPC. In the TF-DEG regulatory network, we found that ZIC2 targeted and activated FN1, CXCL9 and PTGS2, indicating that ZIC2 might also function in NPC by regulating FN1, CXCL9 and PTGS2.

It is reported that the TFs OVOL1 and OVOL2 play critical roles in inducing the transition from mesenchymal to epithelial (MET) in several types of human cancers. As a member of the CXC chemokine family, CXCL10 binds to its receptor CXCR3 to exert biological functions in infectious diseases, immune dysfunction, chronic inflammation, tumor development and metastasis. Overexpression of CXCL10 and CXCR3 play essential roles in advanced cancers, such as basal cell carcinoma, B-cell lymphoma, multiple myeloma and ovarian carcinoma. Inflammatory cytokines including CXCL10, Macrophage-Inhibitory-Protein 1 (MIP1) and interleukin 1 alpha are overexpressed in malignant NPC cells, which may promote the leukocyte infiltrate. These results suggest that OVOL1 and CXCL10 might be correlated with NPC. In the TF-DEG regulatory network, we also found that OVOL1 targeted and repressed CXCL10, suggesting that OVOL1 might also play a role in NPC by mediating CXCL10.

Conclusion

In summary, we used GSE12452 expression profile data downloaded from GEO to study the mechanisms of NPC. A total of 487 genes were selected as DEGs between the NPC samples and the normal nasopharyngeal tissue samples. Several genes (PTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1) might play roles in NPC and might also be used for targeted therapy of NPC in clinical practice. However, further experimental validation is still required to unravel their mechanisms of action in NPC.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Chang ET, Adam H-O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2006;15:1765–77.
3. Sengupta S, Den Boon JA, Chen I-H, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999–8006.
4. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VMY, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50:330–8.
5. Tay JK, Chan SH, Lim CM, Slow CH, Goh HL, Loh KS. The role of Epstein-Barr virus DNA load and serology as screening tools for nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2016, http://dx.doi.org/10.1177/0194599816641038.
6. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). In: Seminars in cancer biology. Elsevier; 2012.
7. Jiang Q, Zhang Y, Zhao M, Li Q, Chen R, Long X, et al. miR-16 induction after CDK4 knockdown is mediated by c-Myc suppression and inhibits cell growth as well as sensitizes nasopharyngeal carcinoma cells to chemotherapy. Tumor Biol. 2016;37:2425–33.
8. Zhang X, Chen X, Zhai Y, Cui Y, Cao P, Zhang H, et al. Combined effects of genetic variants of the PTEN, AKT1, MDM2 and p53 genes on the risk of nasopharyngeal carcinoma. PLoS ONE. 2014;9:e92135.
9. Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer. 2010;10:253.
10. Lung HL, Lo PHY, Xie D, Apte SS, Cheung AKL, Cheng Y, et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer. 2008;123:401–8.
11. Lo PHY, Lung HL, Cheung AKL, Apte SS, Chan KW, Kwong FM, et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res. 2010;70:5567–76.
12. O’Neil JD, Owen TJ, Wood VH, Date KL, Valentine R, Chukwuma MB, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 2008;89:2833–42.
13. Chen H, Yang C, Yu L, Xie L, Hu J, Zeng L, et al. Adenovirus-mediated RNA interference targeting FOXM1 transcription factor suppresses cell proliferation and tumor growth of nasopharyngeal carcinoma. J Gene Med. 2012;14:231–40.
14. Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, et al. Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008;214:445–55.
15. Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, et al. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J Transl Med. 2012;10:10–7.
16. Maiti S. Comprehensive assessment of CNV calling algorithms: a family based study involving monozygotic twins discordant for schizophrenia; 2012.
17. Haynes W. Benjamini–Hochberg method. In: Encyclopedia of systems biology. Springer; 2013. p. 78.
18. Consortium GO. Gene ontology consortium: going forward. Nucleic Acids Res. 2015;43:D1049–56.
19. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2015, gkv1070.
20. Maere S, Heymans K, Kuiper M. BINGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21:3448–9.
21. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21:2933–42.
22. Scherf M, Klingenhoff A, Werner T. Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach. J Mol Biol. 2000;297:599–606
23. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27:431–2.
24. Liao K, Xia B, Zhuang Q-Y, Hou M-J, Zhang Y-J, Luo B, et al. Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-kB/COX-2 pathway. Theranostics. 2015;5:302.
25. Ben Nasr H, Chahed K, Bouaouina N, Chouchane C, PGTS2 (COX-2)—765 G-C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep. 2009;36:193–200.
26. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol. 2005;58:535–8.
27. Shi D, Xiao X, Tian Y, Qin L, Xie F, Sun R, et al. Activating enhancer-binding protein-2α induces cyclooxygenase-2 expression and promotes nasopharyngeal carcinoma growth. Oncotarget. 2015;6:5005.
28. Jia D, Enterz I, Butler C, Foty RA. Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells. BMC Cancer. 2012;12:1.
29. Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol. 2013;44:2028–37.
30. Ma LJ, Lee SW, Lin LC, Chen TJ, Chang IW, HSu HP, et al. Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumor Biol. 2014;35:1703–12.
31. Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin Chim Acta. 2011;412:980–7.
32. Chang KP, Wu CC, Chen HC, Chen SJ, Peng PH, Tsang NM, et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics. 2010;10:2644–60.
33. Hsin LJ, Kao HK, Chen IH, Tsang NM, HSu CL, Liu SC, et al. Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma. PLoS ONE. 2013;8:e80052.
34. Grinberg I, Millen K. The ZIC gene family in development and disease. Clin Genet. 2005;67:290–6.
35. Yang Y, Hwang CK, Junn E, Lee G, Mouradian MM. ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene. J Biol Chem. 2000;275:38863–9.
36. Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A, et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res. 2006;12:83–8.
37. Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, et al. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res. 2007;35:e51.
38. Fernebro J, Francis P, Eden P, Borg Å, Panagopoulos I, Mertens F, et al. Gene expression profiles relate to S518/SSX fusion type in synovial sarcoma. Int J Cancer. 2006;118:1165–72.
39. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S, et al. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE. 2013;8:e76773.
40. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer. Oncol Lett. 2011;2:583–9 [review].
41. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med. 2007;28:87–114.
42. Lo BKK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol. 2010;176:2435–46.
43. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol. 2012;87:865–9.
44. Pellegrino A, Antonacci F, Russo F, Merchionne F, Ribatti D, Vacca A, et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 2004;207:221–7.
45. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, et al. Up-regulation of CXCR chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol. 2007;38:1676–87.
46. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol. 2005;206:68–75.